From: Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study
 |  | Duration of persistence (days) | No. of patients with persistent pregabalin use | ||||
---|---|---|---|---|---|---|---|
 | No. of patients | Mean (SD) | Median (IQR) | > = 90 days ~ < 180 days | > = 180 days ~ < 1 year | > = 1 year ~ < 2 years | > = 2 years |
All cohort | 114,437 | 149.5 (299.8) | 28 (14–118) | 33,570 (29.3) | 22,201 (19.4) | 13,885 (12.1) | 33,570 (29.3) |
Specialties | |||||||
Neurology | 53,910 | 179.3 (330.4) | 41 (14–161) | 18,423 (34.2) | 12,623 (23.4) | 8165 (15.1) | 18,423 (34.2) |
Anesthesiology | 5541 | 189.8 (358) | 42 (14–166) | 1928 (34.8) | 1302 (23.5) | 829 (15) | 1928 (34.8) |
Physiatry | 3151 | 143.4 (301.1) | 28 (14–99) | 845 (26.8) | 566 (18) | 364 (11.6) | 845 (26.8) |
Psychiatry | 430 | 222.8 (383.9) | 56 (21–209) | 162 (37.7) | 117 (27.2) | 80 (18.6) | 162 (37.7) |
Rheumatology | 9201 | 206.6 (366.3) | 47 (21–191) | 3444 (37.4) | 2388 (26) | 1558 (16.9) | 3444 (37.4) |
Others | 42,204 | 93.3 (211.3) | 22 (7–69) | 8768 (20.8) | 5205 (12.3) | 2889 (6.8) | 8768 (20.8) |
Indications | |||||||
Herpes zoster | 34,919 | 89.4 (224.1) | 21 (7–56) | 6405 (18.3) | 3700 (10.6) | 2134 (6.1) | 6405 (18.3) |
Diabetic peripheral neuropathic pain | 13,369 | 221.9 (330.1) | 71 (28–294) | 6044 (45.2) | 4381 (32.8) | 2894 (21.6) | 6044 (45.2) |
Fibromyalgia | 21,051 | 150.8 (302.8) | 28 (14–117) | 6179 (29.4) | 4026 (19.1) | 2470 (11.7) | 6179 (29.4) |
Epilepsy | 3301 | 515.5 (603.5) | 220 (35–814) | 2085 (63.2) | 1748 (53) | 1400 (42.4) | 2085 (63.2) |
Other musculoskeletal diseases | 24,227 | 138.3 (269.8) | 30 (14–113) | 7141 (29.5) | 4499 (18.6) | 2638 (10.9) | 7141 (29.5) |
Others | 17,570 | 158.6 (295.9) | 35 (14–141) | 5716 (32.5) | 3847 (21.9) | 2349 (13.4) | 5716 (32.5) |